Staidson Beijing Biopharma (300204) — Cash Flow Quality Index
Staidson Beijing Biopharma (300204) has a Cash Flow Quality Index of -15.09x as of June 2024. Operating cash flow of CN¥-5.23 Million is below net income of CN¥346.39K, suggesting accrual-heavy earnings not yet converted to cash. Explore 300204 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Staidson Beijing Biopharma Cash Flow Quality Index (2008–2019)
Historical Cash Flow Quality Index for Staidson Beijing Biopharma across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash efficiency ratio of Staidson Beijing Biopharma.
Annual Cash Flow Quality Index for Staidson Beijing Biopharma (2008–2019)
Year-by-year earnings quality comparison for Staidson Beijing Biopharma.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2019 | 1.62x | CN¥44.34 Million | CN¥27.30 Million | ▲ +31.9% |
| 2018 | 1.23x | CN¥165.08 Million | CN¥134.06 Million | ▲ +17.2% |
| 2017 | 1.05x | CN¥273.64 Million | CN¥260.34 Million | ▲ +26.0% |
| 2016 | 0.83x | CN¥212.55 Million | CN¥254.87 Million | ▼ -24.4% |
| 2015 | 1.10x | CN¥231.01 Million | CN¥209.42 Million | ▲ +4.1% |
| 2014 | 1.06x | CN¥206.85 Million | CN¥195.28 Million | ▲ +4.2% |
| 2013 | 1.02x | CN¥111.36 Million | CN¥109.57 Million | ▲ +80.6% |
| 2012 | 0.56x | CN¥90.19 Million | CN¥160.24 Million | ▼ -32.6% |
| 2011 | 0.83x | CN¥87.01 Million | CN¥104.26 Million | ▼ -24.9% |
| 2010 | 1.11x | CN¥63.91 Million | CN¥57.50 Million | ▼ -7.2% |
| 2009 | 1.20x | CN¥42.37 Million | CN¥35.36 Million | ▲ +21.2% |
| 2008 | 0.99x | CN¥16.23 Million | CN¥16.42 Million | — |